(DRUG) Bright Minds Biosciences - Ratings and Ratios
Therapeutics, Selective Agonists, BMB-101, BMB-201, BMB-202
Description: DRUG Bright Minds Biosciences
Bright Minds Biosciences Inc. (NASDAQ:DRUG) is a biotechnology company focused on developing therapeutics for severe and life-altering diseases. The companys portfolio includes selective 5-HT receptor agonists targeting epilepsy, pain, and neuropsychiatry. With a pipeline that includes BMB-101, which has completed Phase 1 trials for an undisclosed seizure disorder, and other candidates like BMB-201 and BMB-202, the company is positioned for potential growth in the biotechnology sector.
From a strategic perspective, Bright Minds Biosciences has established collaborations with reputable institutions such as the National Institutes of Health, University of Texas Medical Branch, and Medical College of Wisconsin. These partnerships are crucial for advancing their research and development efforts, particularly in treating conditions like epilepsy and impulse control disorders. The companys ability to leverage these collaborations will be key to its success.
To evaluate the companys performance, several Key Performance Indicators (KPIs) can be considered. The Market Cap of $183.67M USD indicates the companys size and investor interest. The absence of a P/E ratio suggests that the company is not yet profitable, which is common in the biotechnology industry where companies often invest heavily in R&D before generating earnings. The Return on Equity (RoE) of -10.97% indicates that the company is currently not generating profits from shareholder equity. Other relevant KPIs could include the companys cash burn rate, the number of patents filed or granted, and the progress of their clinical trials.
Given the companys focus on developing treatments for severe diseases and its collaborations with major research institutions, Bright Minds Biosciences is positioned in a potentially high-growth segment of the biotechnology industry. Investors should closely monitor the progress of its clinical trials, particularly the outcome of BMB-101 and the advancement of other pipeline candidates, as these will be critical drivers of the companys future value.
DRUG Stock Overview
| Market Cap in USD | 299m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2021-03-22 |
DRUG Stock Ratings
| Growth Rating | 47.9% |
| Fundamental | 23.2% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 3,176% |
| Analyst Rating | 4.67 of 5 |
DRUG Dividends
Currently no dividends paidDRUG Growth Ratios
| Growth Correlation 3m | 85.6% |
| Growth Correlation 12m | -2.9% |
| Growth Correlation 5y | -5.1% |
| CAGR 5y | 87.72% |
| CAGR/Max DD 3y | 1.01 |
| CAGR/Mean DD 3y | 1.46 |
| Sharpe Ratio 12m | -0.05 |
| Alpha | 990.17 |
| Beta | 0.271 |
| Volatility | 81.12% |
| Current Volume | 80.3k |
| Average Volume 20d | 48.2k |
| Stop Loss | 45.3 (-7.1%) |
| Signal | 1.73 |
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-8.89m TTM) > 0 and > 6% of Revenue (6% = -376.6k TTM) |
| FCFTA -0.04 (>2.0%) and ΔFCFTA 108.4pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| error: NWC/Revenue cannot be calculated (needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.15 (>3.0%) and CFO -7.89m > Net Income -8.89m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 86.56 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (7.08m) change vs 12m ago 52.37% (target <= -2.0% for YES) |
| error: Gross Margin (current vs previous) cannot be calculated (needs Total Revenue and Cost Of Revenue) |
| Asset Turnover -21.36% (prev 0.0%; Δ -21.36pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| error: Interest Coverage Ratio cannot be calculated (needs EBITDA TTM and Interest Expense TTM) |
Altman Z'' 83.25
| (A) 0.99 = (Total Current Assets 52.4m - Total Current Liabilities 605.0k) / Total Assets 52.5m |
| (B) -0.81 = Retained Earnings (Balance) -42.5m / Total Assets 52.5m |
| (C) -0.31 = EBIT TTM -9.06m / Avg Total Assets 29.4m |
| (D) 77.61 = Book Value of Equity 51.8m / Total Liabilities 667.8k |
| Total Rating: 83.25 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 23.19
| 1. Piotroski 0.0pt = -5.0 |
| 2. FCF Yield -0.51% = -0.26 |
| 3. FCF Margin -29.48% = -7.50 |
| 4. Debt/Equity 0.00 = 2.50 |
| 5. Debt/Ebitda -0.02 = -2.50 |
| 6. ROIC - WACC -28.22% = -12.50 |
| 7. RoE -20.81% = -2.50 |
| 8. Revenue Trend data missing |
| 9. Rev. CAGR 0.0% = 0.0 |
| 10. EPS Trend 37.92% = 0.95 |
| 11. EPS CAGR 0.0% = 0.0 |
What is the price of DRUG shares?
Over the past week, the price has changed by +15.41%, over one month by +23.45%, over three months by +71.78% and over the past year by +3800.00%.
Is Bright Minds Biosciences a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of DRUG is around 42.77 USD . This means that DRUG is currently overvalued and has a potential downside of -12.27%.
Is DRUG a buy, sell or hold?
- Strong Buy: 4
- Buy: 2
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the DRUG price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 92.9 | 90.5% |
| Analysts Target Price | 92.9 | 90.5% |
| ValueRay Target Price | 47.1 | -3.5% |
Last update: 2025-09-11 04:36
DRUG Fundamental Data Overview
CCE Cash And Equivalents = 51.4m CAD (Cash And Short Term Investments, last quarter)
Revenue TTM is 0, using Net Income TTM -8.89m + Cost of Revenue 2.62m = -6.28m CAD
P/B = 7.98
Beta = -0.141
Revenue TTM = -6.28m CAD
EBIT TTM = -9.06m CAD
EBITDA TTM = -8.99m CAD
Long Term Debt = 62.8k CAD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 78.2k CAD (from shortTermDebt, last quarter)
Debt = 141.0k CAD (Calculated: Short Term 78.2k + Long Term 62.8k)
Net Debt = -51.2m CAD (from netDebt column, last quarter)
Enterprise Value = 362.3m CAD (413.6m + Debt 141.0k - CCE 51.4m)
Interest Coverage Ratio = unknown (Ebit TTM -9.06m / Interest Expense TTM 0.0)
FCF Yield = -0.51% (FCF TTM -1.85m / Enterprise Value 362.3m)
FCF Margin = -29.48% (FCF TTM -1.85m / Revenue TTM -6.28m)
Net Margin = -141.7% (Net Income TTM -8.89m / Revenue TTM -6.28m)
Gross Margin = -141.7% ((Revenue TTM -6.28m - Cost of Revenue TTM 2.62m) / Revenue TTM)
Tobins Q-Ratio = 6.99 (Enterprise Value 362.3m / Book Value Of Equity 51.8m)
Interest Expense / Debt = 0.88% (Interest Expense 1241 / Debt 141.0k)
Taxrate = 21.0% (US default)
NOPAT = -9.06m (EBIT -9.06m, no tax applied on loss)
Current Ratio = 86.56 (Total Current Assets 52.4m / Total Current Liabilities 605.0k)
Debt / Equity = 0.00 (Debt 141.0k / last Quarter total Stockholder Equity 51.8m)
Debt / EBITDA = -0.02 (Net Debt -51.2m / EBITDA -8.99m)
Debt / FCF = -0.08 (Debt 141.0k / FCF TTM -1.85m)
Total Stockholder Equity = 42.7m (last 4 quarters mean)
RoA = -16.94% (Net Income -8.89m, Total Assets 52.5m )
RoE = -20.81% (Net Income TTM -8.89m / Total Stockholder Equity 42.7m)
RoCE = -21.18% (Ebit -9.06m / (Equity 42.7m + L.T.Debt 62.8k))
RoIC = -21.21% (NOPAT -9.06m / Invested Capital 42.7m)
WACC = 7.01% (E(413.6m)/V(413.7m) * Re(7.01%)) + (D(141.0k)/V(413.7m) * Rd(0.88%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 88.14 | Cagr: 8.18%
Discount Rate = 7.01% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
Fair Price DCF = unknown (Cash Flow -1.85m)
Revenue Correlation: N/A | Revenue CAGR: 0.0%
Rev Growth-of-Growth: N/A
EPS Correlation: 37.92 | EPS CAGR: 0.0%
EPS Growth-of-Growth: -130.0
Additional Sources for DRUG Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle